New technique expands number of functional cord blood stem cells for transplantation

Published on May 8, 2014 at 7:17 AM · No Comments

Adults suffering from diseases such as leukemia, lymphoma, and other blood-related disorders may benefit from life-saving treatment commonly used in pediatric patients. Researchers at the Icahn School of Medicine at Mount Sinai have identified a new technique that causes cord blood (CB) stems cells to generate in greater numbers making them more useful in adult transplantation.

The study, published in the May issue of The Journal of Clinical Investigation, looked at ways to expand the number of hematopoietic stem cells (HSC) in the laboratory required to replenish and renew blood cells. Cord blood stem cells have the ability to rapidly divide in the presence of combinations of growth factors but they often lose their marrow-repopulating potential following cell division. Researchers looked at ways to overcome this limitation by inducing a genetic program by which a stem cell retains its full functional properties after dividing in the laboratory.

"Cord blood stem cells have always posed limitations for adult patients because of the small number of stem cells present in a single collection," said Pratima Chaurasia, PhD, Assistant Professor of Medicine at the Tisch Cancer Institute at Mount Sinai. "These limitations have resulted in a high rate of graft failure and delayed engraftment in adult patients."

Researchers used a technique called epigenetic reprogramming which reshaped cell DNA by treating cells with a combination of histone deacetylase inhibitors (HDACI) and valproic acid. The VPA-treated cells produced a greater number of repopulating cells, and established multilineage hematopoiesis in primary, secondary and tertiary immune-deficient mice.

"We're excited by these results. The findings have important implications for patients battling blood cancers and the difference between success and failure of life saving stem cell transplants." added Ronald Hoffman, MD, Albert A. and Vera G. List Professor of Medicine, Director of Myeloproliferative Disorders Research Program at the Tisch Cancer Institute at Mount Sinai.

This study was supported by a New York Stem Cell Science grant from the Empire State Stem Cell Board, whose mission is to foster a strong stem cell research community in New York State and to accelerate the growth of scientific knowledge about stem cell biology and the development of therapies and diagnostic methods under the highest ethical, scientific, and medical standards for the purpose of alleviating disease and improving human health.

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New technology removes blood clots